McLean, VA, May 22, 2018 --(PR.com
)-- Perthera, Inc., the leading Therapeutics Intelligence Company™, will be hosting a networking breakfast and educational session on Monday, June 4th from 6:30 – 7:30 a.m. for attendees of the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. The breakfast symposium will be held in the Regency D ballroom of the Hyatt Regency McCormick Place, directly adjacent to the McCormick Place.
“We are very excited to host this breakfast symposium at the 2018 ASCO Annual Meeting. With this event we hope to give ASCO attendees more information about who we are and what we do, and the good we can do for oncology patients.” -Neal G. Koller, President & CEO, Perthera, Inc.
The breakfast symposium will feature 3 speakers:
Michael Pishvaian, M.D., Ph.D. presenting: The Perthera Experience of a Comprehensive Case Review and Integration of Multi-omic Molecular Testing for 640 Cancer Patients Through the KYT Program
Chief Medical Officer at Perthera, Inc.
Director, Phase I Clinical Program
Co-Director, Ruesch Center Pancreatic Cancer Program
Lombardi Cancer Center, Georgetown University, Washington DC
Jonathan Brody, Ph.D. presenting: Integrating the Perthera Report into a High Volume Practice of Pancreatic Cancer Patients
Director, Surgical Research
Co-Director, Jefferson Pancreas, Biliary and Related Cancer Center
Thomas Jefferson University, Philadelphia PA
Anthony Conley, M.D. presenting: Initial Experience with the Perthera Report in our Cancer Clinic
Assistant Professor, Department of Sarcoma Medical Oncology
The University of Texas MD Anderson Cancer Center, Houston TX
The 2018 ASCO Annual Meeting will be held at the McCormick Place Convention Center in Chicago from June 1st – 5th, and will host over 25,000 oncology professionals from around the world. In addition to the networking breakfast meeting, Perthera will exhibiting in booth #16024 and have executives on hand during the conference to meet personally with attendees interested in learning more about our role in personalized medicine for cancer treatment.
About Perthera, Inc.:
Perthera is the leading Therapeutic Intelligence Company advancing precision medicine through its Perthera Report™, which precisely matches cancer patients with multiple therapeutic options ranked by highest probability of best outcome. www.perthera.com